Regorafenib
别名: Fluoro-Sorafenib, BAY 73-4506
目录号:S1178 Purity: 99.98%
Regorafenib是一个多靶点抑制剂,作用于VEGFR1,VEGFR2,VEGFR3,PDGFR-β,Kit (c-Kit),RET (c-RET)和Raf-1,在无细胞试验中IC50分别是13 nM,4.2 nM,46 nM,22 nM,7 nM,1.5 nM和2.5 nM。Regorafenib 可诱导自噬。
CAS: 755037-03-7
客户使用Selleck的Regorafenib发表文献204篇
- Nat Med, 2024 10.1038/s41591-024-02824-y
- Nature, 2024 629(8011):450-457
- Signal Transduct Target Ther, 2023 8(1):65
- Cancer Cell, 2022 S1535-6108(22)00312-9
- Cancer Cell, 2022 S1535-6108(21)00662-0
- J Hematol Oncol, 2022 15(1):109
- Cancer Cell, 2021 S1535-6108(21)00659-0
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Gut, 2019 10.1136/gutjnl-2019-318506
- Nat Cell Biol, 2019 21(2):203-213
- Nat Metab, 2019 1(10):985-995
- Gastroenterology, 2017 153(4):1082-1095
- Gastroenterology, 2015 148(7):1438-51
- Cell Rep Med, 2024 S2666-3791(24)00201-5
- NPJ Precis Oncol, 2024 8(1):52
- Biomed Pharmacother, 2024 180:117533
- BMC Cancer, 2024 24(1):1350
- PLoS One, 2024 19(5):e0299522
- BMC Pharmacol Toxicol, 2024 25(1):25
- Discov Oncol, 2024 15(1):709
- Mol Cell, 2023 83(5):803-818.e8
- Exp Mol Med, 2023 55(4):794-805
- J Exp Clin Cancer Res, 2023 42(1):8
- PLoS Biol, 2023 21(9):e3002256
- Pharmacol Res, 2023 192:106789
- Cell Death Dis, 2023 14(1):47
- Br J Cancer, 2023 10.1038/s41416-023-02389-6
- Biomed Pharmacother, 2023 165:115209
- Biochem Pharmacol, 2023 214:115681
- Biochem Pharmacol, 2023 217:115812
- Int J Oncol, 2023 62(2)31
- J Clin Med, 2023 12(23)7267
- Front Med (Lausanne), 2023 10:1095344
- BMB Rep, 2023 10.5483/BMBRep.2023-0072
- Sci Adv, 2023 9(6):eade9238
- Contemp Oncol (Pozn), 2023 27(3):198-210
- Research Square, 2023 10.21203/rs.3.rs-3678387/v1
- Nat Commun, 2022 13(1):7113
- Cell Rep Med, 2022 3(1):100492
- Cancer Lett, 2022 551:215960
- Cell Rep, 2022 41(11):111827
- Cell Rep, 2022 39(3):110712
- Cell Rep, 2022 38(10):110490
- JCI Insight, 2022 7(22e158060)
- Front Immunol, 2022 13:932298
- Cells, 2022 11(22)3663
- Int J Mol Sci, 2022 24(1)686
- Am J Cancer Res, 2022 12(4):1912-1918
- J Pers Med, 2022 12(2)258
- Front Oncol, 2022 12:875219
- Pharmaceuticals (Basel), 2022 15(9)1111
- Sci Rep, 2022 12(1):6345
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Ann Surg Oncol, 2022 29(12):7354-7367
- Life (Basel), 2022 12(8)1258
- Anticancer Drugs, 2022 10.1097/CAD.0000000000001344
- Commun Med (Lond), 2022 2:80
- Adv Sci (Weinh), 2021 e2103360
- ACS Appl Mater Interfaces, 2021 13(41):48478-48491
- Cell Death Dis, 2021 12(12):1084
- Cell Mol Gastroenterol Hepatol, 2021 S2352-345X(21)00223-X
- Food Funct, 2021 10.1039/d0fo02270e
- Commun Biol, 2021 4(1):1067
- Cancer Immunol Immunother, 2021 70(1):203-213
- Int J Mol Sci, 2021 23(1)395
- Int J Mol Sci, 2021 22(21)11770
- Front Pharmacol, 2021 12:632201
- Int J Mol Sci, 2021 22(3)1502
- Mol Cancer Res, 2021 molcanres.0808.2020
- Neoplasia, 2021 23(3):304-325
- Front Oncol, 2021 11:796839
- Pharmaceuticals (Basel), 2021 14(10)971
- Molecules, 2021 26(16)4949
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- J Gastroenterol Hepatol, 2021 10.1111/jgh.15619
- J Cancer, 2021 12(21):6356-6362
- PLoS One, 2021 16(7):e0252689
- PLoS One, 2021 16(7):e0253258
- Mol Biol Rep, 2021 10.1007/s11033-021-06715-0
- Cancer Res, 2020 80(21):4815-4827
- Antiviral Res, 2020 178:104790
- Cancer Cell Int, 2020 19;20:58
- Int J Mol Sci, 2020 18;21(8):2825
- Cancers (Basel), 2020 12(12)E3816
- Arthritis Res Ther, 2020 22(1):160
- Front Oncol, 2020 10:563249
- Front Oncol, 2020 10:694
- Front Oncol, 2020 10:878
- Front Oncol, 2020 10:291
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Onco Targets Ther, 2020 13:7213-7227
- Biochem Biophys Res Commun, 2020 529(3):699-706
- Int J Radiat Biol, 2020 2:1-12
- Transl Cancer Res, 2020 9(11):6820-6832
- VIRGINIA TECH – WAKE FOREST UNIVERSITY, 2020
- EBioMedicine, 2019 41:175-184
- Cell Death Dis, 2019 10(9):672
- Cell Death Dis, 2019 10(10):784
- Br J Cancer, 2019 120(6):612-620
- Cell Rep, 2019 29(3):573-588
- Cell Chem Biol, 2019 10.1016/j.chembiol.2019.04.011
- Cell Commun Signal, 2019 17(1):85
- Cell Biosci, 2019 9:88
- J Med Chem, 2019 10.1021/acs.jmedchem.9b00855
- Br J Pharmacol, 2019 176(6):787-800
- Mol Cancer Ther, 2019 18(11):2146-2157
- Cancers (Basel), 2019 11(4)
- Molecules, 2019 24(7)
- Sci Rep, 2019 9(1):636
- Sci Rep, 2019 9(1):7103
- BMC Microbiol, 2019 19(1):34
- Ann Biomed Eng, 2019 10.1007/s10439-019-02269-2
- Ann Surg Oncol, 2019 26(1):139-147
- Dis Markers, 2019 2019:8964015
- FEBS Open Bio, 2019 9(2):335-347
- Animal Model Exp Med, 2019 2(4):259-268
- Chem Sci, 2018 9(10):2674-2689
- Mol Cancer Ther, 2018 17(12):2610-2621
- Cancer Sci, 2018 109(11):3591-3601
- Oncotarget, 2018 9(56):30869-30882
- Endocr Relat Cancer, 2018 25(4):471-480
- Biochem Biophys Res Commun, 2018 504(4):878-884
- Anticancer Res, 2018 38(4):1967-1977
- BMC Res Notes, 2018 11(1):859
- Sci Transl Med, 2017 14;9(394):eaah6144
- Cancer Res, 2017 77(9):2512-2521
- Arch Toxicol, 2017 91(8):2921-2938
- Clin Sci (Lond), 2017 131(17):2275-2288
- Oncotarget, 2017 8(10):16367-16386
- Oncotarget, 2017 8(12):18832-18847
- Oncotarget, 2017 8(50):87209-87220
- Oncotarget, 2017 9(17):13154-13166
- Oncotarget, 2017 8(1):1449-1468
- Oncotarget, 2017 8(59):99451-99469
- Oncotarget, 2017 8(52):90262-90277
- Oncotarget, 2017 9(3):3605-3618
- Oncotarget, 2017 8(47):83052-83062
- Oncotarget, 2017 8(4):6102-6113
- Oncotarget, 2017 8(69):113444-113459
- Oncotarget, 2017 8(61):103465-103476
- Oncotarget, 2017 8(61):104090-104103
- Molecules, 2017 22(12)
- Sci Rep, 2017 7(1):1502
- Toxicol Sci, 2017 158(1):213-226
- PLoS One, 2017 12(3):e0174151
- Naunyn Schmiedebergs Arch Pharmacol, 2017 390(11):1125-1134
- Mol Biol Cell, 2017 28(7):907-921
- Med Sci Monit, 2017 23:1963-1972
- Curr Cancer Drug Targets, 2017 17(4):386-401
- J Mol Graph Model, 2017 73:48-53
- Exp Ther Med, 2017 14(2):1357-1366
- ACS Nano, 2016 10(11):9999-10012
- Cancer Res, 2016 76(1):117-26
- Oncogene, 2016 10.1038/onc.2016.247
- Bioinformatics, 2016 32(12):i253-i261
- J Cell Physiol, 2016 231(5):1097-105
- J Cell Physiol, 2016 231(10):2286-302
- Oncotarget, 2016 7(30):47954-47965
- Oncotarget, 2016 7(14):17290-300
- Oncotarget, 2016 7(11):12975-96
- Oncotarget, 2016 7(18):26580-92
- Oncotarget, 2016 7(26):40398-40417
- Sci Rep, 2016 6:35308
- PLoS Genet, 2016 12(9):e1006279
- ACS Chem Biol, 2016 11(12):3400-3411
- J Exp Clin Cancer Res, 2015 34:90
- EMBO Mol Med, 2015 7(10):1350-65
- Proc Natl Acad Sci USA, 2015 112(6):1839-44
- Int J Cancer, 2015 136(6):1434-44
- J Cell Physiol, 2015 230(10):2552-78
- J Cell Physiol, 2015 230(1):131-9
- J Cell Physiol, 2015 10.1002/jcp.24961
- Oncotarget, 2015 6(16):14385-98
- Oncotarget, 2015 6(4):1954-66
- Oncotarget, 2015 6(27):23281-96
- Oncotarget, 2015 6(14):11820-32
- Oncotarget, 2015 6(30):28929-37
- Oncotarget, 2015 6(7):4745-56
- Toxicology, 2015 327:10-21
- Drug Metab Dispos, 2015 43(12):1934-7
- Cancer Biol Ther, 2015 16(11):1660-70
- Hepatobiliary Pancreat Dis Int, 2015 14(6):642-50
- J Med Invest, 2015 62(3-4):195-8
- Clin Cancer Res, 2014 20(22):5745-5755
- Clin Cancer Res, 2014 20(22):5768-76
- Cell Death Dis, 2014 5:e1278
- Cancer Cell Int, 2014 14(1):89
- Oncotarget, 2014 5(12):4071-86
- Drug Des Devel Ther, 2014 8:1107-23
- Biomed Res Int, 2014 2014:568693
- Cancer Biol Ther, 2014 15(3):305-16
- Mol Med Rep, 2014 9(1):83-90
- Environ Mol Mutagen, 2014 55(9):704-18
- Assay Drug Dev Technol, 2014 12(9-10):514-26
- Rostock University, 2014 Lange F
- J Clin Endocrinol Metab, 2013 98(6):2502-12
- PLoS One, 2013 8(5):e63240
- Mol Pharmacol, 2013 84(4):562-71
- J Interferon Cytokine Res, 2013 33(4):211-25
- Methods Mol Biol, 2011 685:91-109
化学信息&溶解度
分子量 | 482.82 |
分子式 | C21H15ClF4N4O3 |
CAS号 | 755037-03-7 |
Smiles | CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 97 mg/mL ( 200.9 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 5 mg/mL Water : Insoluble DMSO : 97 mg/mL ( 200.9 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 3 mg/mL Water : Insoluble DMSO : 96 mg/mL ( 198.83 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 97 mg/mL ( 200.9 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 97 mg/mL ( 200.9 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
2% DMSO
30% PEG 300
5% Tween 80
ddH2O
浓度:5mg/ml
(10.36mM)
操作示例:以 1 mL 工作液为例,取20 μL 250 mg/ml的澄清DMSO储备液加到300 μL PEG300中,混合均匀使其澄清;向上述体系中加入50 μL Tween-80,混合均匀使其澄清;然后继续加入630 μL ddH2O定容至 1 mL。工作液请现配现用!
|
|
2%DMSO
98% Corn oil
浓度:5mg/ml
(10.36mM)
操作示例:以 1 mL 工作液为例,取20 μL 250 mg/ml的澄清 DMSO 储备液加到980 μL玉米油中,混合均匀。工作液请现配现用!
|
|
5%DMSO
95% Corn oil
浓度:5mg/ml
(10.36mM)
操作示例:以 1 mL 工作液为例,取50 μL 100 mg/ml的澄清 DMSO 储备液加到950 μL玉米油中,混合均匀。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。